Is This Biotech Stock the Next Big Player in Cancer Treatment?
Goldman Sachs has made a bold prediction regarding Merus, a company at the forefront of innovative cancer therapies. This esteemed financial institution recently began its coverage of Merus with an optimistic buy rating on a pivotal Wednesday, setting an ambitious price target